Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Feasibility and safety of transcaval transcatheter aortic valve implantation: a multicentre European registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of implant depth on hydrodynamic function of the ALLEGRA bioprosthesis in valve-in-valve interventions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.

METHODS AND RESULTS: We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).

CONCLUSIONS: In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.

OriginalsprogEngelsk
TidsskriftEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Vol/bind12
Udgave nummer4
Sider (fra-til)449-55
Antal sider7
ISSN1774-024X
DOI
StatusUdgivet - 20 jul. 2016

ID: 49707528